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Abstract
Background: Mutations in the P53 gene are among the most common genetic abnormalities in human lung cancer. Codon
273 in the sequence-specific DNA binding domain is one of the most frequently mutated sites.
Methodology: To investigate the role of mutant p53 in lung tumorigenesis, a lung specific p53(273H) transgenic mouse
model was developed. Rates of lung cancer formation in the transgenic animals and their littermates were evaluated by
necropsy studies performed in progressive age cohorts ranging from 4 to 24 months. In order to establish the influence of
other common genetic abnormalities in lung tumor formation in the animals, K-Ras gene mutation and p16INK4a (p16)
promoter methylation were evaluated in a total of 281 transgenic mice and 189 non-transgenic littermates.
Principal Findings: At the age extremes of 4–12 and 22–24 months no differences were observed, with very low prevalence
of tumors in animals younger than 12 months, and a relatively high prevalence at age 22 months or older. However, the
transgenic mice had a significant higher lung tumor rate than their non-transgenic counterparts during the age of 13–21
months, suggesting an age-related shift in lung tumor formation induced by the lung-specific expression of the human
mutant p53. Histopathology suggested a more aggressive nature for the transgenic tumors. Older mice (.13 months) had a
significantly higher rate of p16 promoter methylation (17% v 82%). In addition, an age related effect was observed for K-Ras
codons 12 or 13 mutations, but not for codon 61 mutations.
Conclusions/Significance: These results would suggest that the mutant p53(273H) contributes to an acceleration in the
development of spontaneous lung tumors in these mice. Combination with other genetic and epigenetic alterations
occurring after the age of 13 months is intimately linked to its oncogenic potential.
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Introduction
Lung cancer is one of the most deadly cancers worldwide [1–3],
and with more than 160,000 deaths per year. It is the number one
cancer killer in the United States (SEER www.seer.cancer.
gov; [2]). Seventy-five to eighty-five percent of lung cancers are
categorized as non-small cell cancers (NSCLC); and adenocarci-
noma has become the most prevalent NSCLC subtype [1,3].
It has been reported that 50–60% of non-small cell lung cancers
and 90% of small cell lung tumors contain p53 mutations; thus
p53 alterations are among the most common genetic events in this
malignancy [4,5]. The majority of p53 mutations are missense and
found within the sequence-specific DNA-binding domain. Codon
273 is one of the most frequently mutated sites [6–8]. The human
mutant p53(273H), which has the most common substitution
(arginine to histidine), has been shown to have both dominant-
negative and gain-of-function properties [9–13]. Unlike most
tumor-derived mutant p53 proteins, p53(273H) retains partial
sequence-specific DNA-binding and transcriptional activation
functions [14–17]. In addition, p53(273H) has also been reported
to interact with and activate topoisomerase I to induce genomic
instability [13,18] and to promote the reassociation of single-
stranded RNA or DNA to a double-stranded form [19]. Thus
p53(273H) could conceivably lead to increased cell proliferation,
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reduced chemotherapy efficacy [20,21]. p53
270H/+ mice (Murine
p53 codon 270 correspond to human p53 codon 273) develop an
increased incidence of carcinomas and B cell lymphomas
compared to p53
+/2 mice [22].
To study the role of p53 mutation in lung tumorigenesis, animal
models in which the endogenous p53 gene is disrupted or mutated
in a lung-specific manner, or in which mutant p53 transgenes are
expressed in a lung-specific manner, would be of considerable
value. It is of particular interest to generate lung cancer models
which reflect, as closely as possible, human lung cancer
development. To this end, we have developed a line of transgenic
mice expressing the human p53(273H) gene under the transcrip-
tional control of the human surfactant protein C (SP-C) promoter
[23]. Human mutant p53(273H) mRNA and protein were
demonstrated specifically in lung tissue [23,24].
We previously reported the development of lung adenocarci-
nomas in SPCp53(273H) transgenic mice at a higher rate
compared with their littermates at the age range of 13–15 months
[23]. Lung cancer onset data of up to 24 months has now been
collected and summarized in this report. Given their association
with P53 mutations in human lung cancer, we evaluated the rates
of K-ras gene mutation and p16INK4a (p16) promoter methyl-
ation of the lung tumors. c-irradiation of tumors was performed to
evaluate the functional activity of murine p53 in these spontaneous
lung cancers.
Results
Age influences the rate of lung tumor formation
Lung tumor rate and age of onset are summarized in Figure 1.
Overall lung tumor rate was 23.1% (65/281) and 11.6% (22/189)
in the transgenic and non-transgenic mice, respectively (Fisher’s
exact test p=0.01). Peak differences in tumor rate between the
transgenics and non-transgenic mice occurred during the age of
13–21 months (OR: 3.64 p,0.01). However, no significant
differences in the rate of tumor development were observed at
the extreme age ranges (4–12 and 22–24 months).
Histopathologically, the tumors in both transgenic and non-
transgenic groups were well differentiated adenocarcinoma with a
predominantly bronchioloalveolar (BAC) pattern (Figure 2).
However 13 of 24 (54%) tumors examined in transgenic mice
exhibited areas of variant histology, including areas of clear
secretory change, areas of high nuclear grade, areas of oncocytic
change and areas of solid proliferation. These variant histological
patterns are evidence of dedifferentiation, a phenomenon which
human lung tumors readily exhibit. In contrast only 1 of 11 (9%)
tumors examined in the non-transgenic group showed evidence of
dedifferentiation (Fisher’s exact test p=0.14).
Lung tumors express type II pneumocyte differentiation
Immunohistochemical analysis was performed using antibodies
against the surfactant protein C (SP-C) and the Clara cell 10 protein
(CC10), which are commonly used markers to distinguish alveolar
type II cells from Clara cells. Lung tumors collected from the
transgenic mice were all SP-C positive, suggesting that these lesions
expressed alveolar type II pneumocyte differentiation (Fig 3A, 3C).
However, a small percentage of the lung tumor cells also expressed
CC-10 protein (Fig. 3B, 3D) indicating also evidence of Clara cell
differentiation. Human cancers are similarly known to express
evidence of type II pneumocyte and/or Clara cell differentiation.
Incomplete cell cycle arrest after irradiation indicates
both the retention of murine wild type p53 and
reduction in p53 tumor suppression function
One of the most important functions of wild type p53 is its anti-
proliferation property. DNA damage up-regulates wildtype p53
Figure 1. Lung tumor rate in age-matched SPC-p53(273H) transgenic mice and non-transgenic littermates. No difference was found in
lung tumor rate between the transgenic mice and non-transgenic controls at the age range of 4–12 and 22–24 months. The transgenic mice (T) have
a statistically significant (Fisher’s exact test p,0.01) higher lung tumor rate than wildtype controls (C) during the age of 13–21 months.
doi:10.1371/journal.pone.0005563.g001
Age and Lung Cancer in Mice
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repair [25]. Ionizing irradiation induces elevation of wild type p53
protein and results in inhibition of cell proliferation, whereas
knocking-out the p53 gene abolishes irradiation-induced cell cycle
arrest. P53 point mutation in one allele accompanied with
complete loss of the second allele of p53 is a commonly reported
phenomenon in human cancers [26–28]. However, preservation
of a wild type allele has also been reported in human neoplastic
tissue [29–32].
To evaluate whether the murine wild type p53 is intact in the
lung cancers collected from the SPC-p53 (273H) transgenic mice,
we treated the transgenic mice using a
137Cesium c-source at a
dose of 5Gy/mouse. To maximize the evaluation, in vivo Brdu
labeling was performed. The mice were injected with Brdu at dose
Figure 2. Lung tumors and characterization of the SPC-p53(273H) transgenic mice. Lung tumor from the SPC-p53(273H) mice (A). Light
photomicrographs of lung tumor at 1006magnifications with HE staining (B). Immunohistochemical detection of human mutant p53(273H) with
human specific p53 antibody (DO-7) in a lung adenocarcinoma from an SPC-p53(273H) transgenic mouse (C). Lung tumor cells exhibit pleomorphic
nuclei at 4006 magnification (D). Well-differentiated BAC/adenocarcinoma from a transgenic (E) contrasts with a BAC/adenocarcinoma showing
evidence of dedifferentiation into a solid undifferentiated carcinoma (F). Other histological patterns evidencing dedifferentiation included secretory
(G), oncocytic (H) and high nuclear grade (I) and were observed only in the transgenic tumors.
doi:10.1371/journal.pone.0005563.g002
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also injected with Brdu. Both irradiated and control mice were
sacrificed and lung tissues were harvested 2 hours after the Brdu
injection. We analyzed 60 pathological images collected from six
lung tumor bearing mice three of which had been irradiated. The
rate of the BrdU positive cells was 2.61% in the non-irradiated
tumors on average, whereas the proliferating rate was 0.93% in
the irradiated lung tumor samples. Thus, compared to the non-
irradiated tumors, the tumor cell proliferation rate was reduced
2.8 fold after c-irradiation treatment (Fig. 4A, 4B, 4E). In the
normal lung tissues, Brdu positive cell rate was 0.43% without
irradiation, whereas there were almost no Brdu positive cells
(0.009%) observed in the normal lung tissues post irradiation
(Fig. 4C–4E).
The above results suggest that the lung tumors in the p53(273H)
transgenic mice are composed of a mixed population of cells.
Some lung tumor cells retain murine wild type p53, while others
lost the functional murine p53 and continue to proliferate even
after irradiation.
K-ras mutation and p16INK4a (p16) methylation in the
murine lung tumors
The long latency period for tumor development in the
transgenic mice suggests collaboration with other oncogenic events
for lung cancer development. Given the high prevalence of K-ras
and p16 gene deficiencies in human lung cancers [33–36], we
evaluated for K-ras gene mutations and p16 promoter methylation
in the spontaneous lung cancers in both transgenic and non-
transgenic animals.
We analyzed 28 murine lung tumors, 21 from the transgenic
mice and 7 tumors from non-transgenic mice. Six of the transgenic
mice were 4–12 months, and fifteen 13–24 months. All non-
transgenic tumors were collected at the age of 13–24 months,
given their rare occurrence at an earlier age.
It has been reported that K-ras mutations occur mainly in
codons 12, 13 and 61 in murine lung tumors [37], thus we
investigated the DNA sequences of exons 2 and 3 that contain
codons 12, 13 and 61 using PCR amplification followed by DNA
sequencing. Among 21 transgenic tumors, ten tumor samples
Figure 3. Immunohistochemical analysis of the murine lung tumor origin. A lung tumor section was stained with antibody against
surfactant protein C (SP-C), commonly used as a marker for the alveolar type II cell (A). The same tumor was also stained with antibody against the
Clara cell 10 protein (CC10), commonly used as a marker for Clara cell (B). The majority of the lung tumor cells were SP-C positive suggesting that
these lesions arose from the alveolar type II cells (C). A small percentage of the lung tumor cells were CC-10 positive indicating of Clara cell lineage
(D). The arrows pointed the CC-10 positive cells.
doi:10.1371/journal.pone.0005563.g003
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PLoS ONE | www.plosone.org 4 May 2009 | Volume 4 | Issue 5 | e5563Figure 4. Comparison in the rate of cell proliferation between non-irradiated, post-irradiated lung tumors and normal lung tissue,
determined by BrdU labeling. Mice were treated with ionizing radiation (5 Gy/mouse). 22 hours post-irradiation, mice were injected (IP) with
Bromodeoxyuridine (BrdU) at a dose of 100 mg/kg in 0.9% NaCl. Lung tissue and lung tumors were harvested 2 hours after the injection, and then
fixed in 10% neutral buffered formalin for 12 hours. Paraffin embedded tissue was cut and incubated with monoclonal anti-Brdu antibody (DAKO
Corporation, Carpinteria, CA) for Immunohistochemical analysis. Cell proliferation in lung tumors without irradiation (A), post irradiation (B), normal
lung without irradiation (C) as well as normal lung tissue post irradiation (D), were analyzed. The number of BrdU positive cell on a slide was counted
directly under a compound microscope. The averaged percentage of BrdU positive cell was obtained according to thirty random images taken from
each treatment and tissue type group (E). The bars show mean data 6S.D. of thirty random images from three mice per treatment. The arrows
pointed the BrdU positive cells.
doi:10.1371/journal.pone.0005563.g004
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(codons 12 or 13) and six in exon 3 (codon 61). Among 7 non-
transgenic tumors, two mutations were found in exon 2 (codon 12)
and two in codon 61 (Table 1). In all cases, each tumor contained
a single site mutation at the second position of the codon.
Age differences in the type of K-ras mutations were observed,
with a preference for codons 12–13 mutations to occur in the 13–
24 month group (Fig. 5A) with a peak at 16–18 months (3/6 in
transgenics and 5/9 in transgenic and non-transgenic tumors). In
mice younger than 15 months no mutations at codons 12–13 of K-
ras were found (0/10 tumors). The rate of tumors with codon 12–
13 mutations was higher in the 16–18 month cohort compared to
the younger age cohort in the transgenic mice (3/6 vs. 0/10,
Fisher’s exact test p=0.18). Altogether (including non-transgenics)
the 16–18 month cohort had a higher rate of mutations at codons
12–13 of K-ras compared to the younger age cohort (5/9 vs. 0/
10). A similar rate of K-ras mutations were observed between
transgenic and non-transgenic animals (Fig. 5B).
Among four mutations in codon 12, three were G to A
transitions, GGT to GAT; and one was G to T transversion, GGT
to GTT (Fig. 5C). Two mutations were found in codon 13; both
were G to A transitions, GGC to GAC (Fig. 5D). Among eight
mutations in codon 61, six mutations were A to G transitions
(CAA to CGA) and two were A to T transversions, CAA to CTA
(Fig. 5E).
P16 promoter methylation (methylation specific PCR) was
detected in 19 of 28 (68%) lung tumors (Fig. 6). Overall 13 of 21
(62%) transgenic lung tumors and 6 of 7 (86%) non-transgenic
lung tumors contained p16 promoter methylation. Only one of six
(17%) tumors tested at the age cohorts of 4–12 months contained
p16 promoter methylation. In contrast, among the 15 transgenic
tumors collected from the 13–24 month cohorts, 12 (80%) were
found to have p16 promoter methylation (Fisher’s exact test,
p,0.1). Altogether, 18 of 22 (82%) tumors from 13–24 months
(including non-transgenics) had p16 promoter methylation, which
is statistically higher (Fisher’s exact test, p,0.1) than for the 4–12
month group. A similar promoter methylation rate in the tumors
of the transgenics and non-transgenic controls was found (Table 1).
Discussion
The most important function of wild type p53 is the sequence
specific transactivation of target genes. In normal cells, the steady
state level of p53 protein is low and the half-life of p53 is very short
due to the presence of negative regulators, such as Mdm2, JNK
and Pirh2 [38–44]. However, DNA damage (e.g., radiation)
induces a prominent increase in p53 protein levels [45,46]. The
increase in wild type p53 protein in response to DNA damage is
believed to regulate p21 to prevent cells with genetic lesions to
proliferate [47]. Either cell cycle arrest or apoptotic cell death to
remove the damaged cell permanently follows [48]. Mutations of
p53, the vast majority within the sequence-specific DNA-binding
domain of the protein, produce mutant proteins unable to bind to
and transactivate the target genes that mediate tumor suppression
[48–50]. Restoration of p53 function leads to tumor regression in
vivo [51].
The general assumption is that tumor cells with intact p53 will
stop proliferating after irradiation, whereas tumor cells with
deficient p53 will proliferate continually post irradiation. Our
results demonstrated that some tumor cells in the transgenic
animals failed to initiate cell cycle arrest post irradiation, so that
0.93% lung tumor cells were Brdu positive. In comparison, there
were no Brdu positive cells observed in the normal lung tissues
collected from the same mouse post irradiation. Given that even
one copy of intact p53 could cause a complete cell cycle arrest in
mice lungs post irradiation, it follows that the Brdu positive cells
observed in the lung tumors have lost p53 function completely.
Several potential mechanisms for p53 mutant induced tumor-
igenesis have been proposed. One possibility is that mutant p53
inhibits the sequence-specific DNA-binding and transactivation
functions of wild-type p53 in a ‘‘dominant-negative’’ manner by
forming hetero-oligomeric complexes with it [10,11]. Alternative-
ly, certain p53 mutants may possess intrinsic oncogenic potential,
as their introduction into cells lacking endogenous p53 has been
shown to enhance the tumorigenicity of these cells [12,50].
Since human and murine p53 proteins are fully capable of
forming hetero-oligomeric complexes [52], it is therefore possible
that human p53(273H) affected murine wild type p53 function in
the transgenic mice studied through a ‘‘dominant-negative’’ effect
leading to increased cell proliferation [53,54]. Interestingly, the
tumor rate differences observed between the transgenics and the
non-transgenic counterparts beginning at 13 months equalizes
after 22 months, suggesting that the genome instability associated
with senescence [55,56] is diluting any difference that the
transgene effect could produce.
Previously we reported that the level of the mouse wild-type p53
protein was reduced in 10 of 10 tumor samples as compared to
matched normal lung tissue of the transgenic mouse [57]. The
reduction in the level of murine wildtype p53 protein may be
associated with overexpression of p53 ubiquitin–protein ligase
Pirh2 and the ‘‘dominant-negative’’ effect of the mutant p53.
One copy of the wild type p53 is sufficient to cause cell cycle
arrest post irradiation [54], which may explain the delay in tumor
development in our transgenic animals with the two murine
wildtype p53 alleles in addition to the human mutant. This would
also suggests that the p53(273H) has a weak dominant-negative
effect. Previous in vitro studies support this notion [14,17]. At the
age of 13–21 months, when additional genetic and epigenetic
alterations are able to combine with the mutant p53, a significant
Table 1. K-ras mutations and p16INK4a promoter methylation in spontaneous lung neoplasm from SPC-p53(273H) transgenic
mice and Non-Transgenic controls.
Cohort Tumors analyzed K-ras mutation p16 methylation
Codons 12 and 13 Codon 61
SPC-p53(273H) 4–12 months 6 0/6 (0%) 2/6 (33%) 1/6 (17%)
SPC-p53(273H) 13–24 months 15 4/15 (27%) 4/15 (27%) 12/15 (80%)
Non-Transgenic 13–24 months 7 2/7 (29%) 2/7 (29%) 6/7 (86%)
Total 28 6/28 (21%) 8/28 (29%) 19/28 (68%)
doi:10.1371/journal.pone.0005563.t001
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transgenic mice would then be appreciated.
We analyzed 28 spontaneous lung tumors and found that 27%
of lung tumors had K-ras mutations (all somatic) at codons 12–13
at the age of 13–24 months, whereas, no mutation was detected at
these codons at an earlier age. Thus the onset of K-ras mutations
in codons 12 and 13 in murine lung tumor appear to be an age
related phenomenon, appearing at a similar rate in tumor-
developing transgenic and non-transgenic littermates.
Murine lung tumors have been shown to contain a high
frequency of K-ras mutation in codon 61 [37]. This type of Kras
mutation is extremely rare in human tumors, especially lung
cancer. Among 28 lung tumors, eight tumors (29%) contained K-
ras mutation in codon 61, and its frequency was similar between
Figure 5. K-ras mutations in lung tumors of transgenic and non-transgenic control mice. Comparison of K-ras mutation in codons 12–13
and codon 61, (A) between 4–12 months and the 13–24 months transgenic lung tumors, and (B) between the transgenic tumors and the non-
transgenic tumors in age of 13–24 months. Point mutations in (C) K-ras codon 12, (D) K-ras codon 13, and (E) K-ras codon 61.
doi:10.1371/journal.pone.0005563.g005
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12 months transgenic cohort (33%) and the 13–24 months
transgenic cohort (27%), suggesting its lack of association with
age or collaboration with P53 mutations (4–15 months vs. 16–24
months: Fisher’s exact p=0.936).
P16 gene promoter hypermethylation is a common event in
lung cancers [36]; up to 80% in lung adenocarcinomas [58]. Our
study demonstrated aberrant methylation of the p16 gene more
frequently in the 13–24 months cohort than in the 4–12 months
cohort (82% vs. 17% respectively). These results would suggest
that inactivation of p16 by methylation of its promoter region is,
similar to K-ras codons 12–13 mutations, a late age dependent
event contributing to lung tumor formation in the p53(273H)
transgenic mice.
In summary, expression of mutant p53 (273H) in mice lungs
resulted in an age-related demographic shift in lung tumor
formation in the transgenic mice. The latency period for tumors to
develop in these transgenic mice would also suggest that mutant
p53(273H) combine with other age-related genetic or epigenetic
alterations, such as mutation at codon 12 or 13 of K-ras gene and
inactivation of p16 by methylation of its promoter region, to
promote lung tumor formation and progression in the p53(273H)
transgenics. Our model may recapitulate what occurs in human
cancer, where age specific differences have been reported [59,60],
and where tumor formation substantially lags behind the
oncogenic stimulus [61,62]. While p53 and K-ras codons 12/13
mutations and p16 promoter methylation status are well described
in human lung cancers, the influence of age in the likelihood of
these abnormalities to combine with early genetic events has not
been previously explored. Our study supports the multi-step
genetic hits process documented in other malignancies for which
familial cancer clusters are available, and suggests the need to
evaluate age related differences in the pattern of genetic and
epigenetic aberrations linked to lung cancer in patient with this
disease. Relevance to treatment efficacy with conventional
chemotherapy or molecularly targeted treatment may be demon-
strated by such studies.
Materials and Methods
SPC-p53(273H) transgenic and p53 knockout mice
The SPC-p53(273H) transgenic mice were generated by
microinjection of a 6.7-kb fragment of the SPC-p53(273H)
construct into the pro-nuclei of FVB/N mouse zygotes as
previously reported [23].
All lung samples were carefully examined with the use of a
dissecting microscope. All tumors observed were processed for
histological analysis. In addition, 30% of lung samples with no
visible surface tumors were subjected to random histological
analysis. All protocols on animal subjects were approved by The
Ohio State University Institutional Laboratory Animal Care and
Use Committee.
Irradiation
Total body irradiation was performed using a
137Cesium c-
source at a dose of 5Gy/mouse. At 24 h (hours) after irradiation,
mice were sacrificed and lung tumors and normal lung tissues were
harvested.
Figure 6. p16INK4a promoter methylations in lung tumors of transgenic and non-transgenic control mice. Bisulphite-treated tumor
DNA was amplified with primers specific for either a methylated (M) or an unmethylated (U) p16INK4a promoter region (A). Comparison of p16INK4a
promoter methylational rate between 4–12 months and the 13–24 months transgenic lung tumors (B), the transgenic tumors and the non-transgenic
tumors in age of 13–24 months (C).
doi:10.1371/journal.pone.0005563.g006
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Mice were injected (intraperitoneally) with Bromodeoxyuridine
(BrdU) 100 mg/kg in 0.9% NaCl. Lung tumor and normal tissue
were harvested 2 h after the injection, and then the tissues were
fixed in 10% neutral buffered formalin for 12 h. Paraffin
embedded tissue was cut and incubated with monoclonal anti-
Brdu antibody (DAKO Corporation, Carpinteria, CA) for
Immunohistochemical analysis. The number of Brdu positive cell
on a slide was counted directly under a compound microscope
(400 magnification). The average percentage of BrdU positive cells
was obtained from thirty random images (three mice per group).
Methylation Specific PCR (MS-PCR)
One microgramof genomic DNAwas denatured by NaOH (final
concentration, 0.275 M) for 10 min at 37uC. The denatured DNA
wasthentreated with10 mlof10 mMhydroquinone,520 mlof3M
sodium bisulfite at 50uC overnight. The bisulfite-treated DNA was
purified with Qiaquick gel extraction kit (Qiagen, Germany)
according to the manufacturer’s instruction. The DNA was then
precipitated with sodium acetate (final concentration, 0.45 M) and
isopropanol. DNA was eluted with dH2O and used for PCR. The
primers used for the MS-PCR were (U3=GTGATTGGGTGGG-
TATTGAATTTT TGTG, U4=CACACATCATACACACAA
CCCTAAACCA) for unmethylated, (M3=CGATTGGGCGGG-
TATTGAATTTTCGC, M4=CACGTCATACACACGACCC-
TA AACCG) for methylated, and (W1=ACTGAATC TCC-
GCGAGGAAAGCG, W2=GCACACGGCCCTGGGCCGC-
CG) for unmodified sequences flanking the p16 translation start
site [63].
DNA Sequencing
K-ras mutations were identified by utilizing the polymerase
chain reaction (PCR) technique to amplify the second and third
exons (GenBank accession NC_00072, the start codon of K-ras is
located in the second exon) followed by sequence analysis of the
amplified product. Primers used to amplify exon 2 were 59-
AGGCCTGCTGAAAATGACTGA (forward), 59- TTCTTG-
CACCTATGGTTCCCTA (reverse). Primers used to amplify
exon 3 were 59-GGCCAGGAGTGCATTAAGAC (forward), 59-
TGCAGGCATAACA ATTAGCAA (reverse). The primers were
also used for sequencing analysis.
Histology and Immunohistochemistry
Immediately following tissue harvesting, lung tumors and
normal lung tissues were placed in 10% neutral buffered formalin
for 12 h, rinsed with water, and preserved in 16 Phosphate-
buffered Saline (PBS). Paraffin embedded tissue was cut at
4 microns, placed on slides and stained with hematoxylin and
eosin (HE). Additional sections for immunohistochemistry (IHC)
were placed in a 60uC oven for 1 h, cooled, deparaffinized and
rehydrated through xylene and graded ethanol solutions to water
in standard fashion. All slides were quenched for 5 minutes in a
3% hydrogen peroxide solution in methanol to block endogenous
peroxidase.
Antigen retrieval was performed by placing the tissue sections in
a citric acid solution (Dako’s Target Retrieval Solution, pH 6.1)
for 30 minutes at 94uC using a vegetable steamer. Slides were then
placed on a Dako Autostainer immunostaining system for IHC.
Slides were blocked with 10% normal goat serum for 1 h before
application of primary antibody. The detection system used was a
labeled Streptavidin-Biotin Complex. Slides were then counter-
stained in hematoxylin, dehydrated through graded ethanol
solutions and cover slipped.
The antibodies used were: anti-human p53 specific monoclonal
antibody (BD PharMingen, San Diego, CA); anti-b-Actin
monoclonal (Sigma, St. Louis, Missouri); anti-SP-C polyclonal
(Santa Cruz, Santa Cruz, CA); anti-CC10 polyclonal (Santa Cruz,
Santa Cruz, CA) and anti-Brdu monoclonal (DAKO Corporation,
Carpinteria, CA).
Statistical Methods
Given the limited number of lung tumors in certain age cohorts,
age cohorts were combined into three groups, 4–12, 13–21 and
22–24 months for comparisons between transgenic and non-
transgenic mice. In order to investigate how the proportion of lung
tumors vary between transgenic and non-transgenic mice over age
cohorts logistic regression models were used [64]. Using this
model, differences between types of mice for each age cohort
group were tested and odds ratios (OR) estimated through the
interaction of mouse type and age cohort group. The overall
comparison of tumor rates and mouse type were compared by
Fisher’s exact test. Multiple measurements for the % of cells BrdU
positive were averaged for each mouse. Summary statistics were
computed on the average of measurements. Age cohorts for K-ras
mutation or p16 methylation were grouped and compared via
Fisher’s exact test due to the limited number of tumors. P-values
were adjusted for multiple comparisons by the Holm procedure
[65,66]. Briefly the Holm procedure is a modified Bonferroni type
procedure which maintains the experiment-wise error rate.
Adjusted p-values were considered significant at the 0.10 level
given the exploratory nature of these studies and all tests were two
sided. All analyses were performed using STATA statistical
software, version 10.0 [67].
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